[
    [
        {
            "time": "",
            "original_text": "太平洋金工|基金经理深度之华商基金高兵】聚焦高景气赛道，坚守优质成长股",
            "features": {
                "keywords": [
                    "基金经理",
                    "华商基金",
                    "高兵",
                    "高景气赛道",
                    "优质成长股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "基金"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "太平洋金工|基金经理深度之华商基金高兵】聚焦高景气赛道，坚守优质成长股",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【华西医药崔文亮团队】?《药明康德点评报告：业绩延续高速增长，CDMO业务和中国区实验室业务带来核心业绩增量》",
            "features": {
                "keywords": [
                    "药明康德",
                    "CDMO业务",
                    "中国区实验室",
                    "业绩增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华西医药崔文亮团队】?《药明康德点评报告：业绩延续高速增长，CDMO业务和中国区实验室业务带来核心业绩增量》",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药投向标|中成药将加快集采 晶泰科技完成4亿美元D轮融资 镁信健康完成超20亿元C轮融资",
            "features": {
                "keywords": [
                    "中成药",
                    "集采",
                    "晶泰科技",
                    "镁信健康",
                    "融资"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药投向标|中成药将加快集采 晶泰科技完成4亿美元D轮融资 镁信健康完成超20亿元C轮融资",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中航证券给予药明康德买入评级，2021半年报点评：研发外包一体化龙头，延续强劲增长",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "研发外包",
                    "强劲增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中航证券给予药明康德买入评级，2021半年报点评：研发外包一体化龙头，延续强劲增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]